A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

Pegylated arginase I: a potential therapeutic approach in T-ALL

(2010) C. P. Hernandez et al.   BLOOD

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

(2010) Evan S. Glazer et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

(2009) Sam-Mui Tsui et al.   Cancer Cell International

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy

(2008) Thomas Yau et al.   CANCER

Arginine deiminase, a potential anti-tumor drug

(2008) Ye Ni et al.   CANCER LETTERS

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE